Committed to the research and development of the First Class New Biological Medicines

—— Dry eye drops

COMPANY PROFILE

XIAMEN HONG-GUAN BIOTECH CO., LTD.

The company was founded by Chinese American professionals in July 2013 and was introduced to the Amoy Bio Bay as a "double hundred talents of Amoy" in 2015. It is a Sino-foreign joint venture biopharmaceutical company, having a professional R&D team and a number of core technology patents. Combined the latest scientific research with mature technology, the company is committed to the research and development of the first class biological new medicines for the treatment of ocular surface diseases, hypertension, hyperlipemia, hyperglycemia and cardiovascular diseases.

Project Summary

There are about 300 million dry eye patients nationwide and the domestic market value of dry eye drops is more than 15 billion. The number of patients and the market value increase by 10-20% every year. Antibiotic eye drops are the first choice for the treatment of dry eye, but antibiotics should not be used repeatedly. The other kind of eye drops that can be used daily is artificial tears, but it has no anti-inflammatory effect. This project develops a new recombinant protein artificial tear with anti-inflammatory effect, which can be used as an anti-inflammatory drug for long-term repeated use, as well as an supplement of artificial tear , and has a unique effect on improving ocular surface injury.
MORE
Core Competitiveness

Clu, which is short for Clusterin , also known as apolipoprotein J, is a macromolecular chaperone protein of human body and plays a protective role in many physiological processes of diseases. Many scientists believe that Clu can play a therapeutic role in many diseases. For many years, the scientific community has put a lot of effort in the development of medicine from Clu, but it is still unable to prepare the high-purity Clu protein for medical use. So far, there is no report on the development of medicine from Clu protein.
MORE
Scientific Background

Clu is a kind of protein with protective function in human body. The insufficient content of Clu in some patients with cardiovascular diseases and eye diseases will lead to serious consequences. The project uses advanced technology to produce recombinant rClu to compensate the insufficient content of Clu in patients. Animal experiments have proved that rClu can act as the same function as Clu. It can improve and treat cardiovascular diseases and ocular surface diseases. rClu of this project is the only known Clusimilar product that can be developed into medicine in the world.
MORE